



SOLVE
ON.

Science Magazine Recognizes Incyte as #2 “Top Employer” of 2023

October 27, 2023

WILMINGTON, Del.--(BUSINESS WIRE)--Oct. 27, 2023-- *Science* magazine announced today that for the sixth consecutive year, Incyte has been named a top five employer based on its annual survey of approximately 6,800 individuals. Incyte ranked second on this year’s list, two spots higher than its 2022 ranking, and was specifically recognized for its loyal employees, social responsibility and treating employees with respect.

Incyte is proud to be recognized as a top employer by *Science* and seeks to create an environment where innovation, collaboration and respect for each other are prioritized. Incyte is guided by its mission to *Solve On.* for patients around the world – it is a workplace where problems get solved and lives are transformed. Every Incyte employee plays a role in achieving this goal, and the Company is dedicated to creating an atmosphere where employees can grow and thrive to their full potential.

“For more than 20 years, we have focused on creating a culture that fosters innovation, fuels our mission to *Solve On.* and inspires and energizes our employees as they pursue advances for patients in need. Recognitions like this one from *Science* magazine, as well as being named one of [America’s 100 Most Loved Workplaces](#) and one of the [Most Loved Global Workplaces](#) by *Newsweek*, mean so much and help us maintain the energy and excitement that motivate us as individuals, and as a company, every day,” said Paula Swain, Executive Vice President, Human Resources, Incyte.

The complete *Science* magazine Top Employers survey feature, along with individual company rankings, is available in the October 27, 2023 print issue of *Science* and online: <https://www.science.org/content/article/making-happy-workplace-employees>.

About Incyte

Incyte is a Wilmington, Delaware-based, global biopharmaceutical company focused on finding solutions for serious unmet medical needs through the discovery, development and commercialization of proprietary therapeutics. For additional information on Incyte, please visit Incyte.com and follow [@Incyte](#).

View source version on businesswire.com: <https://www.businesswire.com/news/home/20231027752504/en/>

Media

media@incyte.com

Source: Incyte